Antithymocyte Globulin
Antithymocyte Globulin is a pharmaceutical drug with 181 clinical trials. Currently 6 active trials ongoing. Historical success rate of 77.8%.
Success Metrics
Based on 112 completed trials
Phase Distribution
Phase Distribution
43
Early Stage
102
Mid Stage
13
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
72.7%
112 of 154 finished
27.3%
42 ended early
6
trials recruiting
181
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
STOP-T1D Low-Dose (ATG)
Personalized NK Cell Therapy in CBT
Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome
Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases
Tandem Stem Cell Transplantation for Non-Hodgkin's Lymphoma
Clinical Trials (181)
STOP-T1D Low-Dose (ATG)
Personalized NK Cell Therapy in CBT
Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome
Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases
Tandem Stem Cell Transplantation for Non-Hodgkin's Lymphoma
Targeted Dose Study of ATG in Haploidentical Hematopoietic Stem Cell Transplantation
A Reduced-Intensity Conditioning Regimen (Cyclophosphamide, Pentostatin, Anti-thymocyte Globulin) Followed by Haploidentical Hematopoietic Stem Cell Transplant for the Treatment of Patients With Refractory or Recurrent Severe Aplastic Anemia
Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant
Hematopoietic Stem Cell Transplant for Dyskeratosis Congenita or Severe Aplastic Anemia
Gemcitabine Hydrochloride, Clofarabine, and Busulfan Before Donor Stem Cell Transplant in Treating Patients With Refractory B-Cell or T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma
Scleroderma Treatment With Autologous Transplant (STAT) Study
CMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies
Biochemical Correction of Severe EB by Allo HSCT and "Off-the-shelf" MSCs
Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Melanoma
Reduced Intensity Conditioning With Clofarabine, Antithymocyte Globulin (ATG), Total Lymphoid Irradiation (TLI) Followed by Allogeneic Stem Cell Transplant
Busulfan, Cyclophosphamide, & Antithymocyte Globulin Followed by Stem Cell Transplant in Treating Hematologic Cancer
Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma
Efficacy of Romiplostim in Treatment of SAA in Adults Previously Untreated With or Refractory to Immunosuppressive Therapy
Organ-Sparing Marrow-Targeted Irradiation Before Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies
Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 181